Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Pentetreotide
Drug ID BADD_D01725
Description Pentetreotide has been used in trials studying the diagnosis of Cushing's syndrome.
Indications and Usage Not Available
Marketing Status approved; investigational
ATC Code Not Available
DrugBank ID DB12602
KEGG ID D01859
MeSH ID C081788
PubChem ID 72128
TTD Drug ID D0J7CP
NDC Product Code 55463-0032
UNII G083B71P98
Synonyms pentetreotide | indium-pentetreotide | OctreoScan | OctreoScan 111 | indium In 111 pentetreotide | 111-indium-pentetreotide | 111 In -pentetreotide | indium ln-111 pentetreotide | In-111 pentetreotide
Chemical Information
Molecular Formula C63H87N13O19S2
CAS Registry Number 138661-02-6
SMILES CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4= CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)NC(=O)CN(CCN(CCN(CC(=O)O)CC(=O)O)CC(=O)O)CC(=O)O)C (=O)NC(CO)C(C)O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal discomfort07.01.06.001---
Abdominal pain07.01.05.002--
Arthralgia15.01.02.001--
Asthenia08.01.01.001---
Diarrhoea07.02.01.001--
Dizziness02.11.04.006; 17.02.05.003; 24.06.02.007--
Flushing08.01.03.025; 23.06.05.003; 24.03.01.002--
Headache17.14.01.001--
Hyperglycaemia05.06.02.002; 14.06.02.002--
Hyperhidrosis08.01.03.028; 23.02.03.004--
Hypertension24.08.02.001--
Hypoglycaemia05.06.03.001; 14.06.03.001--
Hypotension24.06.03.002--
Injection site pain08.02.03.010; 12.07.03.011---
Nausea07.01.07.001--
Pyrexia08.05.02.003--
Vomiting07.01.07.003--
Hepatic enzyme abnormal13.03.04.026---
The 1th Page    1    Total 1 Pages